파이브로바이올로직스(FBLG)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.45 (-2.36%), 시가총액 $0.01B, 52주 최저~최고 $0.20 ~ $2.28.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headqu
파이브로바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
파이브로바이올로직스의 현재 주가는 $1.45 (-2.36%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
파이브로바이올로직스의 시가총액은 약 $0.01B입니다.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's